Literature DB >> 8637398

A sustained increase in beta-adrenoceptors during long-term therapy with metoprolol and bisoprolol in patients with heart failure from idiopathic dilated cardiomyopathy.

S Yamada1, T Ohkura, S Uchida, K Inabe, Y Iwatani, R Kimura, T Hoshino, T Kaburagi.   

Abstract

Effects of long-term therapy with beta 1-selective antagonists (metoprolol, bisoprolol) on beta-adrenoceptors in lymphocytes of patients with idiopathic dilated cardiomyopathy (DCM) were examined. There was a significant reduction in the number of lymphocyte beta-adrenoceptors in patients with DCM compared to that in healthy volunteers, as demonstrated by a selective decrease in maximum number of binding sites (Bmax) for (-)-[125I]iodocyanopindolol (CYP). A therapy with metoprolol and bisoprolol in these patients caused a marked increase in lymphocyte beta-adrenoceptor density. The significant increase was observed from 2 or 3 months after the start of therapy with these drugs, and it was maintained during the therapy for 24 months. The left ventricular ejection fraction in patients with DCM was improved by the long-term therapy with metoprolol and bisoprolol, and this effect seems to be correlated with an observed enhancement of lymphocyte beta-adrenoceptors in the time course. Also, the increase in lymphocyte beta-adrenoceptors appears to be correlated with a gradual amelioration in circulating catecholamine levels by the long-term therapy with beta-adrenoceptor antagonists in patients with DCM. Thus, the present study suggests that beta-adrenoceptors in lymphocytes of patients with DCM are up-regulated by a long-term therapy with metoprolol and bisoprolol.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8637398     DOI: 10.1016/0024-3205(96)00155-5

Source DB:  PubMed          Journal:  Life Sci        ISSN: 0024-3205            Impact factor:   5.037


  5 in total

Review 1.  Low-level inotropic stimulation with type III phosphodiesterase inhibitors in patients with advanced symptomatic chronic heart failure receiving beta-blocking agents.

Authors:  S F Shakar; M R Bristow
Journal:  Curr Cardiol Rep       Date:  2001-05       Impact factor: 2.931

Review 2.  Metoprolol: a review of its use in chronic heart failure.

Authors:  A Prakash; A Markham
Journal:  Drugs       Date:  2000-09       Impact factor: 9.546

3.  MARCH2 promotes endocytosis and lysosomal sorting of carvedilol-bound β(2)-adrenergic receptors.

Authors:  Sang-oh Han; Kunhong Xiao; Jihee Kim; Jiao-Hui Wu; James W Wisler; Nobuhiro Nakamura; Neil J Freedman; Sudha K Shenoy
Journal:  J Cell Biol       Date:  2012-11-19       Impact factor: 10.539

Review 4.  Effects of beta-blockers on neurohormonal activation in patients with congestive heart failure.

Authors:  D Baran; E M Horn; K Hryniewicz; S D Katz
Journal:  Drugs       Date:  2000-11       Impact factor: 11.431

Review 5.  Novel Molecular Approaches in Heart Failure: Seven Trans-Membrane Receptors Signaling in the Heart and Circulating Blood Leukocytes.

Authors:  Gabriele Giacomo Schiattarella; Fabio Magliulo; Fabio Cattaneo; Giuseppe Gargiulo; Anna Sannino; Anna Franzone; Marco Oliveti; Cinzia Perrino; Bruno Trimarco; Giovanni Esposito
Journal:  Front Cardiovasc Med       Date:  2015-03-16
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.